BioNTech buys China's Biotheus to support oncology strategy
BNT327 has been tested in clinical trials with tumour patients, and Biotheus previously held the rights to commercialize it ...
BioNTech to Acquire Biotheus to Boost Oncology Strategy
Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to ...